On Monday, Gritstone Bio Inc. GRTS revealed interim Section 2 information from the continuing Section 2 examine evaluating GRANITE, its individualized neoantigen-targeting immunotherapy, in frontline microsatellite-stable colorectal most cancers (MSS-CRC).
The examine is designed to judge the scientific advantage of upkeep remedy with GRANITE (GRT-C901/GRT-R902) together with immune checkpoint inhibitors along with fluoropyrimidine/bevacizumab versus fluoropyrimidine/bevacizumab alone.
The corporate says the best profit was noticed within the 50% of sufferers with decrease illness burden at examine entry, as measured by circulating tumor DNA (ctDNA) at examine baseline.
- In all handled populations, GRANITE vs. commonplace of care (SOC) management was related to a 21% relative threat discount of development or demise.33% (13/39) GRANITE and 23% (7/30) of management sufferers stay on examine and freed from development.
- Scientific profit was most notable in sufferers with low illness burden.38% relative threat discount of development or demise with GRANITE vs. SOC management with low ctDNA subgroup
Gritstone plans to evaluate the progression-free survival (PFS) information with the FDA within the coming months and agree on the following steps to advance GRANITE, together with a possible Section 2 or 3 trial utilizing ctDNA ranges as eligibility standards.
Concurrently, Gritstone introduced that it engaged Raymond James as its monetary advisor.
JMP Securities downgraded Gritstone bio from Market Outperform to Market Carry out.
The analyst writes, “with indicators of profit within the low-risk subgroup, however possible inadequate to excite many traders.”
JMP analyst says, “We proceed to love the basics of the GRANITE neoantigen know-how, however as of right this moment see restricted paths ahead that present significant upside to shares from present ranges.”
Value Motion: GRTS inventory is down 57.5% at $0.25 eventually examine Tuesday.
Learn Subsequent:
Market Information and Knowledge delivered to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
